On March 22, 2025, the 22nd China International Exhibition on Laboratory Medicine and Blood Transfusion Instruments and Reagents (CACLP) opened at the Hangzhou International Convention and Exhibition Center. With the theme of “Empowering the IVD Industry for Healthy Development,” the event hosted 1,300+ exhibitors to collectively explore the future trends of the IVD industry!

The exhibition attracted a large number of experts, scholars, researchers, and entrepreneurs from the medical testing field, as well as R&D personnel and industry media representatives from across the entire in vitro diagnostics supply chain.

1. Exhibition Highlights

As a high-tech enterprise specializing in the research, development, production, sales, and service of medical testing technology and related products, Health Gene Tech presented its three major product lines—molecular, biochemical, and immunological—at this exhibition, showcased its latest achievements and innovative capabilities in the field of In Vitro Diagnostics (IVD). The exhibition booth attracted numerous visitors who lingered to view the exhibits, with surging visitor engagement!

2. Major Announcement: Open-Source Primers · Smart Connectivity for All Things — Gene AI Intelligent Entity, Pioneering a New Era in Reagent Development

On the first day of the exhibition, Health Gene Tech unveiled PAMDAX AI — an AI-assisted multiplex PCR design and evaluation system based on pan-genomics — under the theme of “Open-Source Primers, Connecting Everything.” The launch showcased the company's latest breakthroughs in gene AI intelligent entity technology. Dr. Wei Liang, Director of Clinical Laboratories at the First Affiliated Hospital of Ningbo University, Mr. Ding Yu, Chairman and CEO of Health Gene Tech, and Dr. Yong Wu, CTO, were present at the event to witness this significant milestone.

Dr. Dijun Zhang, a researcher at Health Gene Tech Reagent Research Center

At the press conference, Dr. Dijun Zhang, a researcher at Health Gene Tech Reagent Research Center, gave a detailed introduction to the unique features of the PAMDAX AI system: “As a SaaS platform, the biggest highlight of PAMDAX AI is that it does not require any installation by users. Researchers can directly access and use it through a web page. This one-stop multiplex nucleic acid detection reagent kit primer design service streamlines workflow, making scientific research more efficient and convenient.”

Dr. Wei Liang, Director of the Laboratory Department at Ningbo University Affiliated First Hospital

Dr. Wei Liang, Director of the Laboratory Department at Ningbo University Affiliated First Hospital, highly praised the breakthrough features of the PAMDAX AI system: “One of the biggest challenges in the development of traditional test kits is how to avoid non-specific binding and the formation of primer dimers. The intelligent primer design system successfully addresses these pain points by dynamically calculating the ideal range of annealing temperature and GC content, significantly improving the specificity and reliability of the test.”

Dr. Yong Wu, CTO of HGT

Dr. Yong Wu, CTO of Health Gene Tech, stated that the company will continue to focus on the research and development of gene AI intelligent body technology in the future, and plans to expand the coverage of the “Open Source Primer Program” to explore the deep integration of AI technology in fields such as precision diagnosis and genomics.

Ding Yu, Chairman and CEO of HGT

“We commit to breaking down gene assay development through global collaboration, accelerating precision medicine adoption,” announced Ding Yu, Chairman and CEO of Health Gene Tech. “PAMDAX AI will open up some of its primer design algorithms and database resources to global research institutions and enterprises, thereby building a more open and collaborative innovation platform.”

It has been revealed that the PAMDAX AI system is expected to officially launch in June this year, at which point it will be made available to clients. This innovative tool not only represents a significant technological advancement but also indicates the arrival of a more intelligent and efficient era in diagnostic reagent research and development. Stay tuned for the transformative changes brought by PAMDAX AI!

3. Premium Roadshow: Focusing on Cutting-Edge Technology, Discussing the Future of the Industry

During the exhibition, Health Gene Tech's product experts shared the company's latest technologies and product achievements and discussed new trends in the industry with industry peers.

Molecular Reagent Total Solution

Health Gene Tech has deep technical expertise and R&D capabilities in the field of molecular diagnostics and has continuously launched multi-domain solutions for molecular detection. Among these, the flagship product—13 respiratory pathogen panel—enables rapid and precise pathogen identification. Additionally, the company's unique and advanced human papillomavirus (HPV) E6/E7 DNA detection and genotyping kit provides a reliable molecular diagnostic tool for cervical cancer screening and prevention. Additionally, Health Gene Tech offers a comprehensive range of RUO reagent series to provide comprehensive support for clinical research and scientific research.

PAMDAX AI System

As a SaaS (Software as a Service) platform, the PAMDAX AI System can be accessed and used directly via a web browser without any installation required. It provides a one-stop service for designing primers for multiplex nucleic acid detection kits, greatly simplifying the workflow for researchers. The platform integrates a high-quality nucleic acid database and is equipped with three different alignment strategies to accommodate various complex testing scenarios, ensuring high accuracy. Through this approach, the PAMDAX AI System significantly lowers the development threshold for multiplex PCR, encouraging more researchers to participate in the application and innovation of capillary electrophoresis platforms, thereby collectively building a more vibrant and dynamic ecosystem.

In the future, Health Gene Tech will continue with the concept of “innovation-driven development,” continuously increase R&D investment, launch more high-quality products and services, and contribute to the development of the IVD industry!